Vertex Hepatitis C Drug To Enter Phase IIb In ’04; NDA Filing As Early As ’06
Executive Summary
Pivotal trials for Vertex' Hepatitis C treatment merimepodib could begin in 2004, CEO Joshua Boger, PhD, said
You may also be interested in...
Generic Ribavirin Dosing Concerns Can Be Addressed In MedGuide – Geneva
Any concerns about patient safety related to dosing of generic ribavirin products can be addressed in medication guides, Geneva maintains
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials